actin binding LIM protein family member 2Genealiases: []
Q-omics provides the consensus-scored ABLIM2 profile across patient tissues and cancer cell-line models. ABLIM2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ABLIM2 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, ABLIM2 protein abundance shows 30,039 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where ABLIM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABLIM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABLIM2 survival associations across molecular data types. ABLIM2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABLIM2 RNA expression–survival associations across cancer types. High ABLIM2 expression shows unfavorable associations in ACC and STAD, but favorable associations in MESO, THYM, SCLC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ABLIM2 RNA expression.
This table summarizes ABLIM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ABLIM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABLIM2 shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, COAD, CHOL and STAD. The LIHC box plot shows higher ABLIM2 RNA expression in tumor versus normal tissue (log2 FC = +1.010, t-test p < 0.001).
This table shows molecular features associated with ABLIM2 in patient tissues and cancer cell lines. In patient samples, ABLIM2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ABLIM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_SCLC.
